







RESEARCH & INNOVATION

**PROGRAMME 2021 – 27** 



#### PROPOSAL WRITING CAMP

## Session 3: Decoding the Call

- 1. How to understand and analyse a call
- 2. How to deconstruct a call text
- 3. Group work: Practical exercise on call decoding





## 1. Finding, understanding and analysing a call

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/programmes/horizon https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-

search Funding & tender opportunities English EN European Single Electronic Data Interchange Area (SEDIA) Login SEARCH FUNDING & TENDERS 🔻 HOW TO PARTICIPATE 🔻 PROJECTS & RESULTS WORK AS AN EXPERT SUPPORT 🔻 Get started Funding and tenders (1944) Need help? Sort by: Submission status V Type your Keywords. Match whole words only Cascade funding Water4All 2022 Joint Transnational Call "Management of water resources: resilience, adaptation and mitigation to hydroclimatic extreme events and management tools" ✓ GRANTS TENDERS Water4All Horizon Europe (HORIZON) Status Open for submission HORIZON-CL6-2021-CLIMATE-01-02 Deadline model multiple cut-off Topic Submission status 20 March 2023 15:00:00 Brussels time Opening date 01 September 2022 Next deadline Forthcoming (388) Open for submission (420) Closed (1136) Cascade funding **Driving Urban Transitions (DUT) Call 2022** Programming period Open for submission Programme Horizon Europe (HORIZON) Status Select a Programme period.. × v HORIZON-CL5-2021-D2-01-16 Deadline model multiple cut-off Opening date 21 September 2022 Next deadline 03 May 2023 13:00:00 Brussels time Programme part **CETPartnership Joint Call 2022** Cascade funding Programme Horizon Europe (HORIZON) Open for submission HORIZON-CL5-2021-D3-01-04 Deadline model multiple cut-off Mission 20 March 2023 14:00:00 Brussels time 15 September 2022 Next deadline Opening date Select a Mission.. x v **ERC PROOF OF CONCEPT GRANTS** Call for proposal Destination ERC-2023-POC Select a Destination... × × Horizon Europe (HORIZON) Status Open for submission Programme HORIZON ERC Proof of Concept Grants Deadline model multiple cut-off Type of action Quick search on specific priorities

20 October 2022

Opening date

European

20 April 2023 17:00:00 Brussels time

Next deadline

Commission

## Call example

## Future-proofing historical buildings for the clean energy transition

HORIZON-CL5-2023-D4-01-02

Programme Horizon Europe (HORIZON) Status

Type of action HORIZON Research and

Innovation Actions

Opening date 13 December 2022

Call for proposal



Open for submission

**Deadline model** single-stage

Deadline date

20 April 2023 17:00:00

Brussels time



## **Glossary**

CRITICAL RISK	A critical risk is a plausible event or issue that could have a high adverse impact on the ability of the
	project to achieve its objectives. Level of likelihood to occur (Low/medium/high): The likelihood is
	the estimated probability that the risk will materialise even after taking account of the mitigating
	measures put in place.
	Level of severity (Low/medium/high): The relative seriousness of the risk and the significance of its
	effect.
DELIVERABLE	A report that is sent to the Commission or Agency providing information to ensure effective
	monitoring of the project. There are different types of deliverables (e.g. a report on specific activities
	or results, data management plans, ethics or security requirements).
IMPACTS	
	Wider long term effects on society (including the environment), the economy and science, enabled
	by the outcomes of R&I investments (long term). It refers to the specific contribution of the project
	to the work programme expected impacts described in the destination. Impacts generally occur
	some time after the end of the project.

## **Glossary**

#### Control points in the project that help to chart progress. Milestones may correspond to the achievement of a key result, allowing the next phase of the work to begin. They may also be needed at intermediary points so that, if problems have arisen, corrective measures can be **MILESTONE** taken. A milestone may be a critical decision point in the project where, for example, the consortium must decide which of several technologies to adopt for further development. The achievement of a milestone should be verifiable. The goals of the work performed within the project, in terms of its research and innovation content. This will be translated into the project's results. These may range from tackling **OBJECTIVES** specific research questions, demonstrating the feasibility of an innovation, sharing knowledge among stakeholders on specific issues. The nature of the objectives will depend on the type of action, and the scope of the topic. The expected effects, over the medium term, of projects supported under a given topic. The results of a project should contribute to these outcomes, fostered in particular by the **OUTCOMES** dissemination and exploitation measures. This may include the uptake, diffusion, deployment, and/or use of the project's results by direct target groups. Outcomes generally occur during or shortly after the end of the project.

European Commission

## **Glossary**


PATHWAY TO IMPACT	Logical steps towards the achievement of the expected impacts of the project over time, in particular beyond the duration of a project. A pathway begins with the projects' results, to their dissemination, exploitation and communication, contributing to the expected outcomes in the work programme topic and ultimately to the wider scientific, economic and societal impacts of the work programme destination.	
RESEARCH	Results generated by the action to which access can be given in the form of scientific publications,	
	data or other engineered outcomes and processes such as software, algorithms,	
RESULTS	What is generated during the project implementation. This may include, for example, know-how,	
	innovative solutions, algorithms, proof of feasibility, new business models, policy recommendations,	
	guidelines, prototypes, demonstrators, databases and datasets, trained researchers, new	
	infrastructures, networks, etc. Most project results (inventions, scientific works, etc.) are 'Intellectual	
	Property', which may, if appropriate, be protected by formal 'Intellectual Property Rights'.	
TRL	TECHNOLOGY READINESS LEVEL - See annex B	

### Funding & Tenders Portal (FTP) – How to find a call? (I)

Left hand menu:

Horizon Europe

2) Programme part



https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search

#### 2. How to find a call? (II)

## What information do thematic work programmes provide?

- Introduction
- Overview of the scheduled call(s)
- Description of the topics
- Call Key data:
  - Opening date, deadline
  - Type of Action (RIA, CSA, IA, etc)
  - indicative budget per Topic/Call
  - one-stage/two-stage procedure
  - indicative date for evaluation outcome & grant signing
- Budget

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/reference-documents;programCode=HORIZON




EN

**Horizon Europe** 

Work Programme 2023-2024

8. Climate, Energy and Mobility



#### **Partner Search TOOLS**

- Use existing contacts with experience of EU funding programmes
- Use Partner Search on the Funding and tenders portal: <a href="https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search">https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search</a>
- Search the CORDIS database for participants in similar projects in FP7/H2020/HE: <a href="http://cordis.europa.eu/projects/home\_en.html">http://cordis.europa.eu/projects/home\_en.html</a>
- Use social media (e.g. LinkedIn forums)
- European NCP networks, National NCPs, COST actions... <a href="https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp">https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp</a> <a href="https://www.cost.eu/cost-actions-event/browse-actions/">https://www.cost.eu/cost-actions-event/browse-actions/</a>

### 2. How to decode a call text




## Deconstructing a call text

- Specific Conditions: main information about the call
- Expected Outcomes: what is supposed to be achieved
- Scope: presents what exactly is expected to be done





#### Example:



HORIZON-CL6-2021-BIODIV-01-11: What else is out there? Exploring the connection between biodiversity, ecosystems services, pandemics and epidemic risk

**Expected EU contribution per project:** between EUR 4 and 6 Million

**Indicative budget:** Total budget for the topic is EUR 12 Million

Type of Action: Research and Innovation Action

**Eligibility conditions:** see Annex B

**Technology Readiness Level:** Activities are expected to achieve TLR 3-5



Successful proposal will contribute to European Green Deal priorities and the EU biodiversity strategy for 2030, whilst supporting the EU's response to the coronavirus and other zoonotic outbreaks, in the context of EU's goal of leading just digital, economic and ecological transitions that will leave no one behind, One Health approaches, and the future European Health Union. **Projects results** are expected to contribute to [...]



Wildlife microbiomes, whether symbiotic, commensal or pathogenic, and their potential to spread by crossing interspecies barriers, eventually reaching humans via transitional interfaces (e.g. peri-urban, farming areas), are still largely unknown. [...] The impacts of land use and climate change on biodiversity, ecosystem services and pandemics should be also taken into account, as well as any recent IPBES reports on the links between biodiversity and pandemics [...]



## Deconstructing a call text

- Specific Conditions: main information about the call
- Expected Outcomes: what is supposed to be achieved





Outcomes ...→ Impact

Scope: presents what exactly is expected to be done



Research & Innovation Work to be done



Consortium

→ Check Destination as additional /background information



# 3. How to deconstruct a call text Group Work

- Read carefully the *Horizon Europe topic* chosen as an example for the hands-on exercise;
- Sort the information and highlight all words and sentences related to the colour code

Work Consortium Impact Budget



#### HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines

Specific conditions		
Expected EU contribution per project	The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.	
Indicative budget	The total indicative budget for the topic is EUR 40.00 million.	
Type of Action	Research and Innovation Actions	

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 "Tackling diseases and reducing disease burden". To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The scientific and clinical communities use the increased knowledge on pathogens and better understanding of the immune system's role in infectious diseases to develop vaccines with improved efficacy.
- Vaccine manufacturers use more innovative and sustainable manufacturing technologies and improved GMP manufacturing know-how for producing the next generation of vaccines.
- A diversified portfolio of vaccine candidates ready for testing in clinical trials help policy
  makers and funders to make informed decisions about support to vaccine development.
- New innovative and improved design of preclinical/clinical studies that match the features
  of the next generation of vaccines is available for clinical community and regulators, and
  will shorten vaccine development time.

Scope: Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that

#### Horizon Europe - Work Programme 2021-2022 Vs.7.2 for PC Health

more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.

Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates.

The proposals should address several of the following areas:

- Innovation and integration of expertise and capabilities, including alignment of preclinical
  and clinical models, biomarker studies and new vaccine approaches from discovery to late
  stage development, from bench-based research to clinical development of promising
  preventive candidates.
- Application of iterative processes (including cross-learning, back-translation steps, integrative analysis of data) to allow exploitation and integration of novel findings between clinical, preclinical and discovery research and development.
- Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.

Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements be considered. Sex, gender, age and socio-economic factors should be taken into account.

Work

Consortium Impact

#### HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next generation of vaccines

Specific conditions			
Expected EU contribution per project	The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.		
Indicative budget The total indicative budget for the topic is EUR 40.00 million.			
Type of Action	Research and Innovation Actions		
Work	Consortium Impact Budget		

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 "Tackling diseases and reducing disease burden". To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

- The scientific and clinical communities use the increased knowledge on pathogens and better understanding of the immune system's role in infectious diseases to develop vaccines with improved efficacy.
- Vaccine manufacturers use more innovative and sustainable manufacturing technologies and improved GMP manufacturing know-how for producing the next generation of vaccines.
- A diversified portfolio of vaccine candidates ready for testing in clinical trials help policy makers and funders to make informed decisions about support to vaccine development.
- New innovative and improved design of preclinical/clinical studies that match the features of the next generation of vaccines is available for clinical community and regulators, and will shorten vaccine development time.

Scope: Infectious diseases, including antimicrobial resistant (AMR) infections, remain a major threat to health and health security in the EU and globally. The availability of more effective, accessible and affordable vaccines would provide the most cost-effective preventive measure against the health threat of epidemics and AMR pathogens. Vaccines against diseases, such as AIDS, tuberculosis (TB), malaria, neglected tropical diseases, hepatitis C and water-borne diseases are essential to achieve the WHO targets to control the spread of infectious diseases. The first generation of vaccines against some of the pathogens have proven to be suboptimal and not effective enough to protect the population. Many viruses of pandemic potential are variable in their surface antigen composition, and novel technologies are required to develop

efficient vaccines against each new variant efficiently and in a short timeframe. To ensure that more effective, accessible and affordable vaccines against all major infectious diseases become a reality, it is essential to sustain a diverse and modernised vaccine development pipeline.

Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates.


The proposals should address several of the following areas:

- Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late stage development, from bench-based research to clinical development of promising preventive candidates.
- Application of iterative processes (including cross-learning, back-translation steps, integrative analysis of data) to allow exploitation and integration of novel findings between clinical, preclinical and discovery research and development.
- Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.
- Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements be considered. Sex, gender, age and socio-economic factors should be taken into account.

# 3. How to decode a call text Group Work



#### **GROUP WORK:**



**Expected EU contribution per project:** 

**Indicative budget:** 

**Type of Action:** 

**Eligibility conditions:** 

**Technology Readiness Level:** 





### Contact us!

- George Bonas
- Inna Petrenko
- eu-eap\_sticooperation@servicefacility.eu



## Thank you!

#HorizonEU

http://ec.europa.eu/horizon-europe

